Tensha Therapeutics Receives $15,000,000 Series A Financing Round

Feed Type
Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=487f8eeb-007d-4e09-8632-a70fdaac1d0f&Preview=1
Date
9/13/2011
Company Name
Tensha Therapeutics
Mailing Address
55 Cambridge Parkway Cambridge, MA 02142
Company Description
Tensha Therapeutics is developing small molecule bromodomain inhibitors, a new class of epigenetic modulators of gene expression, to treat cancer and other serious disorders.
Website
http://www.tenshatherapeutics.com
Transaction Type
Venture Equity
Transaction Amount
$15,000,000
Transaction Round
Series A
Proceeds Purposes
The company’s lead program, presently in preclinical development, is a first-in-class small molecule aimed at the treatment of BRD4-NUT midline carcinoma (a rare, invariably fatal cancer), acute myeloid leukemias, multiple myeloma, and other malignancies.
M&A Terms
Venture Investor
HealthCare Ventures